Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Piramal settles desflurane litigation with Baxter, set to begin US manufacture in 2012

This article was originally published in Scrip

Executive Summary

Piramal Critical Care, part of India's Piramal group, can manufacture desflurane, a generic version of Baxter's Suprane inhaled anaesthetic agent, in the US next year as part of a patent litigation settlement for the product.

You may also be interested in...

How Piramal Plans To Scale Up In Critical Care, Build On Acquisitions

Peter DeYoung, CEO of Piramal Critical Care, expects to build “profitable growth positions” from the injectable products acquired from Janssen. He is also upbeat about the commercialization prospects in Europe for intrathecal baclofen and the potential launch of the first desflurane generic in the US.

Sun’s Ilumya To Claw Into Japanese Psoriasis Market

Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.

'Covidization' Of Resources Brings Huge Disruption For TB Patients, Researchers

Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts